Differences in physicians' self-reported knowledge of, attitudes toward, and responses to the black box warning on long-acting β-agonists

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 4, 2009, Pages 304-310

  Karpel, Jill P ^a,b   Peters, Jay I ^c   Szema, Anthony M ^d   Smith, Brad ^e   Anderson, Paula J ^f  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e ALTARUM INSTITUTE   (United States)

^f CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; ASTHMA; ATTITUDE TO HEALTH; CLINICAL PRACTICE; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; PHYSICIAN; SELF DISCLOSURE; UNITED STATES;

ADRENERGIC BETA-AGONISTS; ASTHMA; DRUG LABELING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; SELF DISCLOSURE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77958070082     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60529-7     Document Type: Article

References (13)

1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: Global Initiative for Asthma, National Heart, Lung, and Blood Institute; 2006.
3. Physicians' Desk Reference. Montvale, NJ: Thomson PDR; 2007.
4. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ (Clin Res Ed). 1993; 306:1034-1037.
5. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
6. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285: 2594-2603.
7. 2- agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583-2593.
8. 2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Sys Rev. 2005(4):CD005533.
9. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-930.
10. Oppenheimer J, Aaronson D. Impact of recent black box warnings in the allergy world. Ann Allergy Asthma Immunol. 2007;99:364-366.
11. Wechsler ME, Lehman E, Lazarus SC, et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519-526.
12. 2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118:809-816.
13. Nelson HS, Dorinsky PM. Safety of long-acting β-agonists. Ann Intern Med. 2006;145:706; author reply, 8-10.